Liquid profiling for cancer patient stratification in precision medicine – current status and challenges for successful implementation in standard care
Circulating tumor DNA (ctDNA), accurately described by the term liquid profiling (LP), enables real-time assessment of the tumor mutational profile as a minimally invasive test and has therefore rapidly gained traction, particular for the management of cancer patients. By LP, tumor-specific genetic...
Main Authors: | Haselmann Verena, Hedtke Maren, Neumaier Michael |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2022-08-01
|
Series: | Journal of Laboratory Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/labmed-2022-0066 |
Similar Items
-
Liquid Profiling for Cancer Patient Stratification in Precision Medicine—Current Status and Challenges for Successful Implementation in Standard Care
by: Verena Haselmann, et al.
Published: (2022-03-01) -
Liquid profiling of circulating tumor DNA in colorectal cancer: steps needed to achieve its full clinical value as standard care
by: Maren Hedtke, et al.
Published: (2022-05-01) -
Status of liquid profiling in precision oncology – the need for integrative diagnostics for successful implementation into standard care
by: Froelich Matthias F., et al.
Published: (2022-08-01) -
Assessment of Circulating Nucleic Acids in Cancer: From Current Status to Future Perspectives and Potential Clinical Applications
by: Gabriella Cirmena, et al.
Published: (2021-07-01) -
The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer
by: Aleksandra Bożyk, et al.
Published: (2022-10-01)